Bristol Myers Squibb Advances Protein Degradation Cancer Drug into Human Trials

Bristol-Myers Squibb (NYSE:BMY) has advanced BMS-986506, a molecular glue candidate, into Phase 1 trials for clear cell renal cell carcinoma in partnership with Evotec. The program marks the first clinical-stage asset from their protein degradation collaboration, triggering a milestone payment to Evotec. The trial adds another point of interest alongside Bristol-Myers Squibb's existing oncology and immunology portfolio, with factors to track including safety signals, early signs of activity, and updates on the broader CELMoD platform in oncology.